AstraZeneca Targets 28% Growth For 2010

Anglo-Swedish pharmaceutical company AstraZeneca intends to build upon positive revenue performance in Russia during 2009. The drugmaker will attempt to drive sales growth rates by expanding its innovative portfolio and also plans to localise production. BMI believes Russia should form a key part of AstraZeneca's recently-publicised push into emerging markets and we see commitment to invest as a key indication of Russia's importance to

To read the full article, please choose one of the following options: